.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,629,305

« Back to Dashboard

Claims for Patent: 5,629,305

Title: Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
Abstract:A synergistic pharmaceutical combination and composition are disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a proton pump inhibitor such as e.g., omeprazole or lansoprazole, which increases intragastric pH, and a therapeutic amount of an acid degradable antibacterial compound such as a penicillin or a macrolide. In particular, the combination is directed to the treatment of infections caused by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.
Inventor(s): Eek; Arne T. (Trosa, SE), Sj ostrand; Sven Erik (S odert alje, SE)
Assignee: ASTRA Aktiebolag (Sodertalje, SE)
Application Number:08/441,766
Patent Claims: 1. A pharmaceutical composition for the treatment of gastritis and peptic ulcer comprising a therapeutically effective amount of a proton pump inhibitor which increases intragastric pH; and a therapeutically effective amount of an acid degradable antibacterial compound.

2. The composition according to claim 1 wherein the proton pump inhibitor is omeprazole, lansoprazole or a salt thereof.

3. The composition according to claim 1 wherein the acid degradable antibacterial compound is a weak base antibacterial compound.

4. The composition according to claim 1 wherein the acid degradable antibacterial compound is selected from the group consisting of a penicillin and a macrolide.

5. The composition according to claim 4 wherein the penicillin is benzylpenicillin and the macrolide is an erythromycin or a clarithromycin.

6. The composition according to claim 1 wherein the acid degradable antibacterial compound is clarithromycin.

7. An oral pharmaceutical composition for the treatment of gastritis and peptic ulcer caused by Helicobacter pylori infections comprising as active ingredients

(a) a therapeutically effective amount of a proton pump inhibiting compound which thereby increases the intragastric pH; and

(b) a therapeutically effective amount of at least one acid degradable antibacterial compound.

8. A synergistic pharmaceutical combination of a therapeutic amount ranging from about 1-200 mg of proton pump inhibiting compound or salt thereof, which increases intragastric pH; and a therapeutic amount ranging from about 250 mg to 10g of an acid degradable antibacterial compound for the treatment of gastritis and peptic ulcer.

9. The synergistic pharmaceutical combination according to claim 8 wherein the acid degradable antibiotic is selected from the group consisting of a penicillin and a macrolide.

10. A synergistic pharmaceutical combination comprising a therapeutic amount of omeprazole or salt thereof and a therapeutic amount of a erythromycin for the treatment of gastritis and peptic ulcer.

11. A synergistic pharmaceutical combination comprising a therapeutic amount of omeprazole or salt thereof and a therapeutic amount of an acid degradable penicillin for the treatment of gastritis and peptic ulcer.

12. A synergistic pharmaceutical combination comprising therapeutic amount of omeprazole or salt thereof and a therapeutic amount of benzylpenicillin for the treatment of gastritis and peptic ulcer.

13. A synergistic pharmaceutical combination comprising a therapeutic amount of lansoprazole or salt thereof and a therapeutic amount of an erythromycin for the treatment of gastritis and peptic ulcer.

14. A synergistic pharmaceutical combination comprising a therapeutic amount of lansoprazole or salt thereof and a therapeutic amount of clarithromycin for the treatment of gastritis and peptic ulcer.

15. A synergistic pharmaceutical combination comprising a therapeutic amount of lansoprazole or salt thereof and a therapeutic amount of a penicillin for the treatment of gastritis and peptic ulcer.

16. A method for treatment of gastritis and peptic ulcer caused by Helicobacter pylori comprising first orally administering to a patient suffering therefrom a therapeutically effective amount of a composition comprising a proton pump inhibiting compound which is an inhibitor of gastric acid secretion; and thereafter or concomitantly administering a therapeutically effective amount of an acid degradable antibacterial compound.

17. The method according to claim 16, wherein the acid degradable antibacterial compound is selected from the group consisting of a macrolide and a penicillin.

18. The method according to claim 17, wherein the macrolide is selected from the group consisting of an erythromycin and a clarithromycin.

19. The method according to claim 17, wherein the antibacterial compound is benzylpenicillin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc